Galina F Makhaeva1, Nadezhda V Kovaleva1, Elena V Rudakova1, Natalia P Boltneva1, Sofya V Lushchekina1,2, Irina I Faingold3, Darya A Poletaeva3, Yuliya V Soldatova3, Raisa A Kotelnikova3, Igor V Serkov1, Anatoly K Ustinov1, Alexey N Proshin1, Eugene V Radchenko1,4, Vladimir A Palyulin1,4, Rudy J Richardson5,6,7,8. 1. Institute of Physiologically Active Compounds Russian Academy of Sciences, 142432 Chernogolovka, Russia. 2. Emanuel Institute of Biochemical Physics Russian Academy of Sciences, 119334 Moscow, Russia. 3. Institute of Problems of Chemical Physics of Russian Academy of Sciences, 142432 Chernogolovka, Russia. 4. Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia. 5. Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI 48109, USA. 6. Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. 7. Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA. 8. Michigan Institute for Computational Discovery and Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Abstract
New hybrids of 4-amino-2,3-polymethylenequinoline with different sizes of the aliphatic ring linked to butylated hydroxytoluene (BHT) by enaminoalkyl (7) or aminoalkyl (8) spacers were synthesized as potential multifunctional agents for Alzheimer's disease (AD) treatment. All compounds were potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity toward BChE. Lead compound 8c, 2,6-di-tert-butyl-4-{[2-(7,8,9,10- tetrahydro-6H-cyclohepta[b]quinolin-11-ylamino)-ethylimino]-methyl}-phenol exhibited an IC50(AChE) = 1.90 ± 0.16 µM, IC50(BChE) = 0.084 ± 0.008 µM, and 13.6 ± 1.2% propidium displacement at 20 μM. Compounds possessed low activity against carboxylesterase, indicating likely absence of clinically unwanted drug-drug interactions. Kinetics were consistent with mixed-type reversible inhibition of both cholinesterases. Docking indicated binding to catalytic and peripheral AChE sites; peripheral site binding along with propidium displacement suggest the potential of the hybrids to block AChE-induced β-amyloid aggregation, a disease-modifying effect. Compounds demonstrated high antioxidant activity in ABTS and FRAP assays as well as inhibition of luminol chemiluminescence and lipid peroxidation in mouse brain homogenates. Conjugates 8 with amine-containing spacers were better antioxidants than those with enamine spacers 7. Computational ADMET profiles for all compounds predicted good blood-brain barrier distribution (permeability), good intestinal absorption, and medium cardiac toxicity risk. Overall, based on their favorable pharmacological and ADMET profiles, conjugates 8 appear promising as candidates for AD therapeutics.
New hybrids of n class="Chemical">4-amino-2,3-polymethylenequinoline with different sizes of the aliphatic ring linked to butylated hydroxytoluene (BHT) by enaminoalkyl (7) or aminoalkyl (8) spacers were synthesized as potential multifunctional agents for Alzheimer's disease (AD) treatment. All compounds were potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity toward BChE. Lead compound 8c, 2,6-di-tert-butyl-4-{[2-(7,8,9,10- tetrahydro-6H-cyclohepta[b]quinolin-11-ylamino)-ethylimino]-methyl}-phenol exhibited an IC50(AChE) = 1.90 ± 0.16 µM, IC50(BChE) = 0.084 ± 0.008 µM, and 13.6 ± 1.2% propidium displacement at 20 μM. Compounds possessed low activity against carboxylesterase, indicating likely absence of clinically unwanted drug-drug interactions. Kinetics were consistent with mixed-type reversible inhibition of both cholinesterases. Docking indicated binding to catalytic and peripheral AChE sites; peripheral site binding along with propidium displacement suggest the potential of the hybrids to block AChE-induced β-amyloid aggregation, a disease-modifying effect. Compounds demonstrated high antioxidant activity in ABTS and FRAP assays as well as inhibition of luminol chemiluminescence and lipid peroxidation in mouse brain homogenates. Conjugates 8 with amine-containing spacers were better antioxidants than those with enamine spacers 7. Computational ADMET profiles for all compounds predicted good blood-brain barrier distribution (permeability), good intestinal absorption, and medium cardiac toxicity risk. Overall, based on their favorable pharmacological and ADMET profiles, conjugates 8 appear promising as candidates for AD therapeutics.
Authors: Katarina Spilovska; Jan Korabecny; Eugenie Nepovimova; Rafael Dolezal; Eva Mezeiova; Ondrej Soukup; Kamil Kuca Journal: Curr Top Med Chem Date: 2017 Impact factor: 3.295
Authors: Galina F Makhaeva; Eugene V Radchenko; Vladimir A Palyulin; Elena V Rudakova; Alexey Yu Aksinenko; Vladimir B Sokolov; Nikolay S Zefirov; Rudy J Richardson Journal: Chem Biol Interact Date: 2012-11-02 Impact factor: 5.192
Authors: E R Milaeva; O A Gerasimova; Zhang Jingwei; D B Shpakovsky; S A Syrbu; A S Semeykin; O I Koifman; E G Kireeva; E F Shevtsova; S O Bachurin; N S Zefirov Journal: J Inorg Biochem Date: 2008-02-01 Impact factor: 4.155
Authors: Sergey O Bachurin; Galina F Makhaeva; Elena F Shevtsova; Natalia P Boltneva; Nadezhda V Kovaleva; Sofya V Lushchekina; Elena V Rudakova; Ludmila G Dubova; Daria V Vinogradova; Vladimir B Sokolov; Alexey Yu Aksinenko; Vladimir P Fisenko; Rudy J Richardson; Gjumrakch Aliev Journal: Sci Rep Date: 2019-03-19 Impact factor: 4.379
Authors: Galina F Makhaeva; Nadezhda V Kovaleva; Natalia P Boltneva; Elena V Rudakova; Sofya V Lushchekina; Tatiana Yu Astakhova; Igor V Serkov; Alexey N Proshin; Eugene V Radchenko; Vladimir A Palyulin; Jan Korabecny; Ondrej Soukup; Sergey O Bachurin; Rudy J Richardson Journal: Molecules Date: 2022-02-04 Impact factor: 4.411
Authors: Maria V Grishchenko; Galina F Makhaeva; Yanina V Burgart; Elena V Rudakova; Natalia P Boltneva; Nadezhda V Kovaleva; Olga G Serebryakova; Sofya V Lushchekina; Tatiana Y Astakhova; Ekaterina F Zhilina; Evgeny V Shchegolkov; Rudy J Richardson; Victor I Saloutin Journal: ChemMedChem Date: 2022-03-23 Impact factor: 3.540